CD38: A Potential Therapeutic Target in Cardiovascular Disease

Area of Science:

• Biochemistry
• Cardiology
• Molecular Biology

Background:

• Cardiovascular disease (CVD) is associated with intracellular calcium dysregulation, aging, reduced nicotinamide adenine dinucleotide (NAD+) levels, and decreased sirtuin activity.
• CD38 is identified as the primary mammalian NADase, catalyzing the production of molecules that influence calcium release and NAD+ metabolism.
• Dysregulation of CD38 activity impacts NAD+ content and sirtuin function, linking it to age-related diseases and potentially CVD.

Purpose of the Study:

• To review the structure, regulation, function, and drug development targeting CD38 within the cardiac context.
• To explore the mechanisms of CD38 action in cardiovascular disease models.
• To evaluate CD38 as a potential therapeutic target for cardiovascular diseases.

Main Methods:

• Literature review of existing research on CD38 and cardiovascular disease.
• Analysis of CD38's enzymatic activity and its downstream effects on cellular signaling pathways.
• Examination of preclinical data and proposed therapeutic strategies targeting CD38.

Main Results:

• CD38 catalyzes the formation of cADPR, NAADP, and ADPR, leading to Ca2+ release.
• CD38 activity results in NAD+ consumption and diminished sirtuin activity, contributing to cellular dysfunction.
• Current research highlights a significant association between CD38 and various cardiovascular conditions.

Conclusions:

• CD38 plays a critical role in regulating NAD+ metabolism and calcium signaling relevant to cardiovascular health.
• Understanding CD38's mechanisms in CVD models is crucial for therapeutic development.
• CD38 emerges as a promising novel therapeutic target for managing cardiovascular diseases.